Clinical Trials

GastrointestinalGynecologic

70 enrolled

Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05718219 2025-08-13

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors

Phase 1 Active not recruiting

408 enrolled

Advanced Solid Tumors

NCT03812549 2025-03-04

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

29 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT05504278 2025-01-27

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

144 enrolled

Advanced Non-Small Cell Lung Cancer

NCT05979818 2024-11-19

BRIO

6 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04220944 2024-08-01

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

45 enrolled

Carcinoma, Hepatocellular

NCT06431685 2024-05-28

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

10 enrolled

CNS

Meningeal Carcinomatosis

NCT05088967 2024-01-16

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Phase 1 Terminated

6 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05164458 2023-12-28

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

320 enrolled

Phase 1 Active not recruiting

Advanced Solid Tumors

NCT04906044 2023-11-18

STARS-RC03

46 enrolled

Tislelizumab

NCT05119998 2023-08-18

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

48 enrolled

Solid Tumor

NCT05026593 2023-07-19

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

60 enrolled

SCLC

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

19 enrolled

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

42 enrolled

Advanced Lung Cancer

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

High-Risk Resectable NSCLC

NCT03545971 2023-02-28

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

53 enrolled

Advanced Solid Tumors

NCT04177290 2023-02-27

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05118334 2023-02-23

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03758001 2023-02-22

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

38 enrolled

Advanced Solid Tumor

NCT05225116 2023-02-08

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

20 enrolled

Carcinoma, Hepatocellular

NCT02937116 2022-10-14

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

233 enrolled 30 charts

Tumor-Agnostic

Neoplasms

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Phase 1 Terminated

9 enrolled

SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT05363722 2022-05-06

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

80 enrolled

Carcinoma, Hepatocellular

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04427774 2021-07-20

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Phase 1 Terminated

8 enrolled

Advanced or Metastatic Solid Tumors

NCT03568539 2021-06-01

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

39 enrolled 16 charts

Advanced/Metastatic Solid Malignancies

NCT04400851 2020-09-03

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors

18 enrolled

Tumor-Agnostic

Neoplasms

NCT03987867 2020-07-07

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04104074 2020-07-07

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

20 enrolled